LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company engaged in the development of treatments for ocular diseases, disclosed a significant share purchase by Gabriele Cerrone, the Executive Chairman, on Monday. Cerrone, through Panetta Partners Limited, acquired an additional 50,000 ordinary shares at a price of $1.03 each, escalating his total ownership to 9,851,570 shares or 29.12% of the company's issued share capital.
The company is known for its work on OK-101, a novel therapy designed for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), conditions currently underserved in the pharmaceutical market. OK-101, which targets the ChemR23 G-protein coupled receptor, has demonstrated anti-inflammatory and pain-reducing effects in mouse models. The drug's unique formulation includes a lipid anchor intended to prolong its presence in the ocular environment, potentially offering an advantage over existing treatments.
OKYO recently completed a Phase 2, multi-center, double-blind, placebo-controlled trial for OK-101, which indicated statistical significance in multiple endpoints for DED treatment. The company is also preparing to initiate a Phase 2 trial for OK-101 targeting NCP, aiming to address the unmet need for an FDA-approved therapy for this particular ocular condition.
This latest share purchase by a key executive is a noteworthy development for OKYO Pharma, as it may reflect confidence in the company's pipeline and future prospects. The company's focus on innovative ocular therapies continues to be a central part of its growth strategy in the biopharmaceutical sector.
The information in this article is based on a press release statement from OKYO Pharma Limited.
In other recent news, OKYO Pharma's Executive Chairman, Gabriele Cerrone, has increased his ownership stake, adding 80,000 ordinary shares via Panetta Partners Limited, bringing his total ownership to 9,801,570 shares. This acquisition underscores Cerrone's confidence in OKYO Pharma's future prospects. The company has also made significant strides in its research and development, securing crucial U.S. patents for its dry eye disease (DED) treatment, OK-101, and preparing for a Phase 2 trial of OK-101 for neuropathic corneal pain (NCP), a condition currently lacking an FDA-approved therapy.
H.C. Wainwright analysts have maintained a Buy rating for OKYO Pharma, indicating the potential of OK-101 to become the first FDA-approved therapy for NCP. Furthermore, OKYO Pharma's CEO, Dr. Gary S. Jacob, is set to appear on Bloomberg TV, where he will offer insights into the company's business strategy and ongoing projects. These recent developments highlight OKYO Pharma's commitment to addressing unmet medical needs in ocular diseases.
InvestingPro Insights
Following the recent share acquisition by Executive Chairman Gabriele Cerrone, investors are taking a closer look at OKYO Pharma Limited's financial health and market performance. According to InvestingPro data, OKYO has a market capitalization of approximately $34.85 million, reflecting its size within the biopharmaceutical industry. The company's financials show a challenging picture, with a negative adjusted P/E ratio over the last twelve months as of Q4 2024, standing at -2.07. This indicates that OKYO is not currently generating profits relative to its share price.
InvestingPro Tips reveal that OKYO's stock price has experienced a significant decline over the last week, with a total return of -10.43%. This could be a point of concern for investors, especially considering the company's stock often moves counter to the market trend. Additionally, the company's short-term obligations exceed its liquid assets, which may raise questions about its financial stability in the near future.
It's also worth noting that OKYO does not pay dividends, which might be a consideration for income-focused investors. For those interested in exploring further, InvestingPro offers additional tips on OKYO Pharma, providing a more comprehensive understanding of the company's financial position and market behavior.
Despite the challenges reflected in these metrics, the recent share purchase by a key executive could be seen as a vote of confidence in the company's potential, especially as OKYO progresses with its clinical trials for novel ocular therapies. Investors keen on following OKYO's journey and uncovering more in-depth analysis can find a total of 6 additional InvestingPro Tips on the company's profile.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.